By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk…

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…